Automated And Closed Cell Therapy Processing Systems Market Size, Share & Trends Analysis Report By Workflow (Separation, Expansion, Apheresis), By Type (Stem Cell Therapy), By Scale (Commercial Scale), By Region, And Segment Forecasts, 2026 - 2033
Description
Automated And Closed Cell Therapy Processing Systems Market Summary
The global automated and closed cell therapy processing systems market size was estimated at USD 1.67 billion in 2025 and is projected to reach USD 7.44 billion by 2033, growing at a CAGR of 20.73% from 2026 to 2033. The growing popularity of regenerative medicine & cell therapies, coupled with a range of benefits offered by automation technologies for developing these therapies, is expected to propel market growth.
In addition, the growing integration of software technologies and advanced therapy development processes is expected to drive market growth. Rising investments by bio manufacturers for developing cellular therapy products through rounds of series funding are anticipated to offer lucrative growth opportunities. Moreover, the increasing demand for scalable, safe, and contamination-free cell therapy manufacturing solutions, highlighted by innovations such as animal origin-free formulations, is driving the market’s growth.
Growing Cell & Gene Therapy Pipeline Driving Manufacturing Demand
The expanding pipeline of cell and gene therapies, including CAR-T, NK, TCR-based, and emerging allogeneic modalities, is significantly increasing the need for scalable, high-throughput manufacturing systems. As more programs advance into clinical development, developers are experiencing rising pressure to enhance production capacity while maintaining strict quality and regulatory standards. This growth is also accompanied by an increasing number of autologous therapies, each requiring individualized processing, which further amplifies the strain on manual and semi-automated workflows.
With multiple late-stage cell therapy candidates moving closer to commercialization, manufacturers are prioritizing automated and closed systems to support larger batch volumes, greater operational efficiency, and stronger contamination control. Traditional manual processes are proving insufficient for meeting accelerated timelines, reproducibility expectations, and the higher throughput required as the market expands. Automated platforms that integrate cell isolation, activation, expansion, and formulation steps are becoming essential for reducing cycle times and ensuring consistent product quality.
In addition, the shift toward allogeneic, “off-the-shelf” cell therapies is reshaping production strategies and driving demand for systems that can support true industrial-scale manufacturing. These therapies rely on repeatable, high-yield processes that automated and closed platforms are better equipped to deliver. Collectively, the broadening therapeutic pipeline is prompting companies to invest heavily in next-generation manufacturing technologies to ensure scalability, efficiency, and sustained competitiveness in a rapidly evolving market.
Global Automated and Closed Cell Therapy Processing Systems Market Report Segmentation
This report forecasts revenue growth at global, regional and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global automated and closed cell therapy processing systems market report based on workflow, type, scale, and region:
The global automated and closed cell therapy processing systems market size was estimated at USD 1.67 billion in 2025 and is projected to reach USD 7.44 billion by 2033, growing at a CAGR of 20.73% from 2026 to 2033. The growing popularity of regenerative medicine & cell therapies, coupled with a range of benefits offered by automation technologies for developing these therapies, is expected to propel market growth.
In addition, the growing integration of software technologies and advanced therapy development processes is expected to drive market growth. Rising investments by bio manufacturers for developing cellular therapy products through rounds of series funding are anticipated to offer lucrative growth opportunities. Moreover, the increasing demand for scalable, safe, and contamination-free cell therapy manufacturing solutions, highlighted by innovations such as animal origin-free formulations, is driving the market’s growth.
Growing Cell & Gene Therapy Pipeline Driving Manufacturing Demand
The expanding pipeline of cell and gene therapies, including CAR-T, NK, TCR-based, and emerging allogeneic modalities, is significantly increasing the need for scalable, high-throughput manufacturing systems. As more programs advance into clinical development, developers are experiencing rising pressure to enhance production capacity while maintaining strict quality and regulatory standards. This growth is also accompanied by an increasing number of autologous therapies, each requiring individualized processing, which further amplifies the strain on manual and semi-automated workflows.
With multiple late-stage cell therapy candidates moving closer to commercialization, manufacturers are prioritizing automated and closed systems to support larger batch volumes, greater operational efficiency, and stronger contamination control. Traditional manual processes are proving insufficient for meeting accelerated timelines, reproducibility expectations, and the higher throughput required as the market expands. Automated platforms that integrate cell isolation, activation, expansion, and formulation steps are becoming essential for reducing cycle times and ensuring consistent product quality.
In addition, the shift toward allogeneic, “off-the-shelf” cell therapies is reshaping production strategies and driving demand for systems that can support true industrial-scale manufacturing. These therapies rely on repeatable, high-yield processes that automated and closed platforms are better equipped to deliver. Collectively, the broadening therapeutic pipeline is prompting companies to invest heavily in next-generation manufacturing technologies to ensure scalability, efficiency, and sustained competitiveness in a rapidly evolving market.
Global Automated and Closed Cell Therapy Processing Systems Market Report Segmentation
This report forecasts revenue growth at global, regional and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global automated and closed cell therapy processing systems market report based on workflow, type, scale, and region:
- Workflow Outlook (Revenue, USD Million, 2021 - 2033)
- Separation
- Expansion
- Apheresis
- Fill- Finish
- Cryopreservation
- Others
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Stem Cell Therapy
- Non Stem Cell Therapy
- Scale Outlook (Revenue, USD Million, 2021 - 2033)
- Pre-Commercial/ R&D Scale
- Commercial Scale
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
130 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Product Segment
- 1.2.2. Disease Area
- 1.2.3. Technology
- 1.2.4. End Use
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Biomarker
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
- Chapter 3. Middle East Diagnostic Reagents for Infectious Diseases Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Growing regulatory authorizations for multiplex and high-sensitivity reagent kits
- 3.2.1.2. Increasing expansion of national public-health and reference laboratories
- 3.2.1.3. Growing adoption of multiplex testing and automation to improve throughput and speed
- 3.2.1.4. Increasing need for antimicrobial-resistance (AMR) surveillance and diagnostics
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of advanced reagent kits and testing platforms
- 3.2.2.2. Insufficient laboratory infrastructure and limited skilled workforce
- 3.3. Middle East Diagnostic Reagents for Infectious Diseases Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.2. PESTEL Analysis
- Chapter 4. Middle East Diagnostic Reagents for Infectious Diseases Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Middle East Diagnostic Reagents for Infectious Diseases Market: Product Movement Analysis
- 4.3. Middle East diagnostic reagents for infectious diseases market Size & Trend Analysis, By Product, 2021 to 2033 (USD Million)
- 4.4. Molecular Reagents
- 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Immunoassay Reagents
- 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Rapid Test Reagents
- 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Serology Reagents
- 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.8. Controls and Calibrators
- 4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.9. Other Reagents
- 4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Middle East Diagnostic Reagents for Infectious Diseases Market: Disease Area Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Middle East Diagnostic Reagents for Infectious Diseases Market: Disease Area Movement Analysis
- 5.3. Middle East diagnostic reagents for infectious diseases market Size & Trend Analysis, By Disease Area, 2021 to 2033 (USD Million)
- 5.4. Respiratory Infections
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Vector-Borne & Tropical Diseases
- 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Enteric Infections
- 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Sexually Transmitted Infections (STIs)
- 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.8. Other Emerging / High-Burden Infectious Diseases
- 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Middle East Diagnostic Reagents for Infectious Diseases Market: Technology Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Middle East Diagnostic Reagents for Infectious Diseases Market: Technology Movement Analysis
- 6.3. Middle East diagnostic reagents for infectious diseases market Size & Trend Analysis, By Technology, 2021 to 2033 (USD Million)
- 6.4. Molecular Diagnostics
- 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Immunoassays
- 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Point-of-Care Reagents
- 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Multiplex Platforms
- 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Middle East Diagnostic Reagents for Infectious Diseases Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Middle East Diagnostic Reagents for Infectious Diseases Market: End Use Movement Analysis
- 7.3. Middle East diagnostic reagents for infectious diseases market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
- 7.4. Hospitals & Clinics
- 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Diagnostic Laboratories
- 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Point-of-Care / Decentralized Testing Sites
- 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Public Health Agencies & National Reference Labs
- 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Academic & Research Institutes
- 7.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Middle East Diagnostic Reagents for Infectious Diseases Market: Country Estimates & Trend Analysis
- 8.1. Regional Dashboard
- 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 8.3. Middle East
- 8.3.1. Saudi Arabia
- 8.3.1.1. Key country dynamics
- 8.3.1.2. Regulatory framework/ reimbursement structure
- 8.3.1.3. Competitive scenario
- 8.3.1.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.2. UAE
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Regulatory framework/ reimbursement structure
- 8.3.2.3. Competitive scenario
- 8.3.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.3. Kuwait
- 8.3.3.1. Key country dynamics
- 8.3.3.2. Regulatory framework/ reimbursement structure
- 8.3.3.3. Competitive scenario
- 8.3.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.4. Oman
- 8.3.4.1. Key country dynamics
- 8.3.4.2. Regulatory framework/ reimbursement structure
- 8.3.4.3. Competitive scenario
- 8.3.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.5. Qatar
- 8.3.5.1. Key country dynamics
- 8.3.5.2. Regulatory framework/ reimbursement structure
- 8.3.5.3. Competitive scenario
- 8.3.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.6. Rest of Middle East
- 8.3.6.1. Key country dynamics
- 8.3.6.2. Regulatory framework/ reimbursement structure
- 8.3.6.3. Competitive scenario
- 8.3.6.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Share Analysis, 2024
- 9.4. List of Key Certification Providers/Scheme Owners
- 9.5. Company Profiles/Listing
- 9.5.1. F. Hoffmann-La Roche Ltd
- 9.5.1.1. Company overview
- 9.5.1.2. Financial performance
- 9.5.1.3. Product benchmarking
- 9.5.1.4. Strategic initiatives
- 9.5.2. Abbott
- 9.5.2.1. Company overview
- 9.5.2.2. Financial performance
- 9.5.2.3. Product benchmarking
- 9.5.2.4. Strategic initiatives
- 9.5.3. QIAGEN
- 9.5.3.1. Company overview
- 9.5.3.2. Financial performance
- 9.5.3.3. Product benchmarking
- 9.5.3.4. Strategic initiatives
- 9.5.4. bioMérieux
- 9.5.4.1. Company overview
- 9.5.4.2. Financial performance
- 9.5.4.3. Product benchmarking
- 9.5.4.4. Strategic initiatives
- 9.5.5. Bio-Rad Laboratories, Inc.
- 9.5.5.1. Company overview
- 9.5.5.2. Financial performance
- 9.5.5.3. Product benchmarking
- 9.5.5.4. Strategic initiatives
- 9.5.6. Seegene Inc.
- 9.5.6.1. Company overview
- 9.5.6.2. Financial performance
- 9.5.6.3. Product benchmarking
- 9.5.6.4. Strategic initiatives
- 9.5.7. Thermo Fisher Scientific, Inc.
- 9.5.7.1. Company overview
- 9.5.7.2. Financial performance
- 9.5.7.3. Product benchmarking
- 9.5.7.4. Strategic initiatives
- 9.5.8. SD Biosensor
- 9.5.8.1. Company overview
- 9.5.8.2. Financial performance
- 9.5.8.3. Product benchmarking
- 9.5.8.4. Strategic initiatives
- 9.5.9. Mindray
- 9.5.9.1. Company overview
- 9.5.9.2. Financial performance
- 9.5.9.3. Product benchmarking
- 9.5.9.4. Strategic initiatives
- 9.5.10. Astragene
- 9.5.10.1. Company overview
- 9.5.10.2. Financial performance
- 9.5.10.3. Product benchmarking
- 9.5.10.4. Strategic initiatives
- 9.5.11. Hologic
- 9.5.11.1. Company overview
- 9.5.11.2. Financial performance
- 9.5.11.3. Product benchmarking
- 9.5.11.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
